The type of ALK-expressing tumor (ALCL, IMT, NSCLC, neuroblastoma, melanoma, etc.)and possible concomitant activation of oncogenes, such as MYCN or K-RAS in neuroblastomas, for example, are also determinant for the choice of one particular signaling pathway by tumor cells [42,44]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.